Navigation Links
Arpida Announces Review of Iclaprim NDA by FDA Advisory Committee in November 2008
Date:10/14/2008

REINACH, Switzerland, October 14 /PRNewswire-FirstCall/ -- Arpida Ltd. (SWX: ARPN) today announced that it has received notice from the U.S. Food and Drug Administration (FDA) that the agency's Anti-Infective Drugs Advisory Committee will discuss the New Drug Application (NDA) for intravenous iclaprim in complicated Skin and Skin Structure Infections (cSSSI) during its meeting on 18-20 November 2008. An Advisory Committee can be requested by FDA as part of the review process of an NDA or supplemental NDA.

Iclaprim is a hospital antibiotic drug candidate with potent bactericidal (killing) activity against MRSA and an extended range of important pathogens. To date, Arpida has filed marketing applications for intravenous iclaprim in the treatment of complicated Skin and Skin Structure Infections in the U.S.A., Canada and the European Union.

Dr Paul Hadvary, Head of Development of Arpida Ltd., commented: "We are delighted to have an opportunity to present iclaprim to leading experts in the anti-infective field and to discuss important features of our NDA with the Advisory Committee."

About Arpida Ltd.

Arpida (SWX: ARPN) is a biopharmaceutical company headquartered in Reinach, Switzerland with operations in Switzerland and the USA. It focuses on the discovery, development and commercialisation of novel drugs that seek to overcome the growing problem of microbial resistance. The most advanced compounds include an antibacterial under regulatory review and an antifungal in Phase III.

Arpida's leading product candidate is intravenous iclaprim, a potent antibacterial that targets severe infections requiring hospital treatment, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). The clinical programme for the first indication, complicated skin and skin structure infections (cSSSI), has been completed. The submission of the NDA to the US FDA was completed in March 2008. The FDA has defined that the Prescription
'/>"/>

SOURCE Arpida Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Arpida Completes Enrolment in Phase II "Intravenous-to-Oral" Switch Trial With Oral Iclaprim
2. Arpida Enrols First Patients in "Intravenous-to-Oral" Switch Trial With Oral Iclaprim
3. Arpida Provides Further Comments on the Pivotal Phase III Trials
4. Arpida Invited to Present Data on Iclaprim at Scientific Conference
5. Neurobiological Technologies Announces FDA Agreement to Consolidate Viprinex Phase 3 Trials Accelerating Time to Pivotal Data
6. Facet Solutions Announces Completion of 6 Month Follow-Up in US Pilot Study
7. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
8. XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week
9. SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen
10. In celebration of World Hospice and Palliative Care Day, FHSSA Announces Seven New Partnerships Between U.S. Organizations and African Hospices
11. Burcon announces GRAS status for Puratein(R) & Supertein(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... BASKING RIDGE, N.J. , Oct. 22, 2014 ... (RMANJ), a world-renowned leader in the field ... more rapid approach to embryonic screening. The research ... American Society for Reproductive Medicine (ASRM) meeting in ... chromosome screening (CCS) and single gene defect (SGD) ...
(Date:10/22/2014)... , October 22, 2014 ... Disposable Gloves Market (Product type, Form, End user, Application ... Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, ... disposable gloves market. Based on key trends tracked, it ... valued at $7.9 billion by 2020, registering a CAGR ...
(Date:10/22/2014)... , Oct. 21, 2014   BioNano Genomics ... latest genomics research centers to purchase an ... the National Cancer Institute (NCI), NIH Intramural Sequencing ... Before Irys, obtaining a comprehensive view of a ... sequencing (NGS) does not deliver the scalability or ...
Breaking Medicine Technology:New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 2New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 3Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 2Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 3Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 4BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 3
... Advice ® Networks, the nation,s leading provider of ... hosted a panel of primary care physicians at ... held in Philadelphia, PA. The panel, comprised of ... the country with diverse patient populations, spoke candidly ...
... YORK, Jan. 12, 2011 InstaCare Corp. (OTC ... and non-prescription diagnostics, home testing products for the ... to patient diabetes programs, and a leading developer ... today announced that the company,s Board of Directors ...
Cached Medicine Technology:Healthy Advice® Networks Physicians Discuss Patient Adherence Challenges at National Conference 2InstaCare Corp. Announces 2011 Genstrip Guidance Report Penned by William Walling, CFA 2
(Date:10/25/2014)... -- Not getting the right amount of sleep might ... suggests. Those who sleep less or more than ... be more prone to developing the chronic condition, which ... authors concluded that duration and quality of sleep are ... bowel diseases. "Both short and long durations of ...
(Date:10/25/2014)... HealthDay Reporter FRIDAY, Oct. 24, 2014 ... spot increased risks for certain cancers, one might think that ... But a new study suggests that, at least with colon ... their genes doubled their risk of colon cancer were no ... "It didn,t make any difference, not at all," said ...
(Date:10/22/2014)... On October 22, CBS will air an episode ... fictional and real. The Charles E Holman Morgellons ... advocacy and philanthropy in the battle against Morgellons Disease, ... impart truth and clarity about this misunderstood and routinely ... about Morgellons Disease (MD) and most people ...
(Date:10/22/2014)... Amy Norton HealthDay Reporter , ... on the three Ebola cases in Dallas. But, mental health ... to Americans. President Barack Obama on Friday appointed an ... which has infected two Dallas nurses who cared for a ... Health Presbyterian Hospital. But the U.S. cases are miniscule ...
(Date:10/22/2014)... California (PRWEB) October 22, 2014 Hay House ... Move Beyond Addiction and Upgrade Your Life (Paperback; $10.82) written ... of Yoga & Recovery. This book is meant to ... in a life of recovery. , Recovery 2.0 is ... 12 Steps; Recovery 2.0 is a guide for what comes ...
Breaking Medicine News(10 mins):Health News:Sleep Duration Linked to Ulcerative Colitis Risk in Study 2Health News:Knowing Genetic Risk for Cancer May Not Change Behavior 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 3Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 2Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 3Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3
... in some way. For some people, the most convenient ... in exercise machines to help burn calories and increase ... preferences, budget and health, some aerobic exercise machines may ... of Mayo Clinic Health Letter covers some options: ...
... a clear indication in a scientific journal regarding a ... the drug was tested on human participants, which turned ... timely emergency care services, the participants would have been ... reasons for the mishap of the trial, blamed gross ...
... of Newcastle disease on an East Lothian farm has led to ... // is usually fatal for birds and a 3km protection zone ... Fenton Barns, Drem, to prevent its spread. ,According to ... not linked to bird flu. However it can spread rapidly in ...
... the funds that was provided by the US administration ... to men in Swaziland. ,According to the U.S. ... of the program and that it violated government policy ... procedure. ,Over the past 12 months around 300 ...
... surgery was made at a major conference on brain tumours ... , ,According to the Irish Cancer Society, in spite ... higher rate of success and any damge to the delicate ... that there were 316 new cases of primary brain tumour ...
... advanced nations of the world today, Britain had to face ... in Europe' last week. //In a recent report by CABE ... of the nation's population can be declared obese and overweight. ... (CABE) with its headquarters in London works towards improving people's ...
Cached Medicine News:Health News:Home Is Where the Gym Is 2Health News:Bush Administration Proposes End of Funding of Anti-AIDS Program in Swaziland 2Health News:Awake Surgery to treat Brain tumours 2
... tip, the Finntip Wide is designed especially ... like genomic DNA. This tip eliminates the ... is excellent for use with extremely viscous ... diameter of the orifice is 1.1 mm ...
For restriction digests, immuno-precipitations, enzyme assays, TLC spotting and others...
The Ultra Micro tip for the Eppendorf and Nichiryo/BenchMate 0.5-10 L pipettors is perfect for working with low volume samples....
... easy way to order tips. Each box contains ... D10mL, which contains 200 tips (4 bags of ... Packs of 200 tips per pack. Bulk Packs ... easily be opened for quick access to Gilsons ...
Medicine Products: